PD-1

[Nature Cell Biology] The authors reported that cancer cells with aberrant expression of glutamate decarboxylase 1 rewired glutamine metabolism for the synthesis of γ-aminobutyric acid (GABA)—a prominent neurotransmitter—in non-nervous tissues.

[Nature Communications] The authors developed and optimized a CXCR4-targeted mRNA nanoparticle platform to effectively induce p53 expression in hepatocellular carcinoma models.

[Nature Reviews Clinical Oncology] The authors describe the roles of the diverse post-translational modifications of PD-L1, including phosphorylation, palmitoylation, glycosylation, acetylation and ubiquitination.

[Science Advances] Researchers found that TSC1/TSC2 loss defined a distinct subtype of NSCLC characterized as inflamed tumor microenvironment and superior sensitivity to immune checkpoint blockade.

[Cell Reports] Using single-cell sequencing, scientists showed that tumor-induced lymphocytes include skewed T cell clonotypes, which were characterized by exhaustion or nonexhaustion signatures.

[Journal of Clinical Investigation] Investigators observed that anti–PD-1 therapy depends on IL-2 signaling, which raised the possibility that a lack of IL-2 limited anti–PD-1–induced effector T cell expansion.